Question 77

Sitagliptin (Januvia) is a drug used in the treatment of type 2 diabetes.

Sitagliptin is specifically indicated for the management of type 2 diabetes, as it helps to regulate blood sugar levels by enhancing insulin secretion and decreasing glucagon levels.

A) schizophrenia.

Sitagliptin does not have any therapeutic role in the treatment of schizophrenia. Schizophrenia is a severe mental disorder that requires antipsychotic medications, which are distinctly different from the diabetes medications like sitagliptin.

B) Parkinson's disease.

Sitagliptin is not used for Parkinson's disease treatment. Parkinson's is a neurodegenerative disorder that typically requires dopaminergic therapies, unlike sitagliptin, which targets glucose metabolism.

C) type 2 diabetes.

This option is correct as sitagliptin is specifically approved for the treatment of type 2 diabetes. It functions by enhancing the body's own ability to lower blood sugar levels when they are elevated.

D) type 1 diabetes.

Sitagliptin is not indicated for type 1 diabetes treatment. Type 1 diabetes is characterized by the autoimmune destruction of insulin-producing beta cells, requiring insulin replacement therapy, which sitagliptin cannot provide.

Conclusion

Sitagliptin is definitively utilized for the management of type 2 diabetes due to its mechanism of action that supports insulin secretion and blood glucose regulation. Each of the other options fails to relate to the drug's indication, as they involve conditions that require different pharmacological approaches.